- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Biogen IDEC (NASDAQ:BIIB): Current price $177.31
On Wednesday, Biogen announced the positive, full first-year results from its two-year pivotal Phase 3 ADVANCE study of Plegridy (peginterferon beta-1a), its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks. The data are being presented at the American Academy of Neurology’s 65th Annual Meeting, and show that Plegridy significantly lowered multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.